Recent Updates
Recently added Catalysts
HCA Positive Sentiment

INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare reports THIRD quarter 2025 results RAISES 2025 Guidance Nashville, Tenn.

Friday, October 24, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: HCA Healthcare, Inc. has announced its financial and operational results for the third quarter of 2025, which ended on September 30. The results display an improvement compared to the previous year, prompting the company to raise its guidance for the full year of 2025. This is noted as a positive indicator of the company's future performance and financial health.
Price reaction · baseline $440.16 (2025-10-23 close) · hit after-hours · 1 other HCA headline(s) in the window, move may be shared
day 0 close
+1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • HCA Healthcare reported strong financial and operating results for Q3 2025.
  • The company raised its guidance for 2025, indicating confidence in future performance.

Full Press Release Details

FOR IMMEDIATE RELEASE
INVESTOR CONTACT: MEDIA CONTACT:
Frank Morgan Harlow Sumerford
615-344-2688 615-344-1851
HCA Healthcare reports THIRD quarter 2025 results
RAISES 2025 Guidance
Nashville, Tenn., October 24, 2025 – HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the third quarter ended September 30, 2025.
Key third quarter metrics (all percentage changes compare 3Q 2025 to 3Q 2024 unless otherwise noted):

Frequently Asked Questions

What quarter results did HCA Healthcare report?

HCA Healthcare reported its third quarter results for 2025.

When was the HCA Healthcare announcement made?

The announcement was made on October 24, 2025.

What did HCA Healthcare raise for 2025?

HCA Healthcare raised its guidance for 2025.

What time period do the reported results cover?

The results cover the third quarter ended September 30, 2025.

ShareAdd on Google
Tags: HCA Viatris Investor Conferences Healthcare HCA Healthcare Q3 results 2025 guidance financial performance
Last updated: Oct 24, 2025

Biotech snapshot

Cash runway
$1415M liquidity · $0M/mo burn
Low dilution risk